Literature DB >> 7495280

Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.

M H Zheng1, Y Fan, A Panicker, A Smith, T Robertson, S Wysocki, P Robbins, J M Papadimitriou, D J Wood.   

Abstract

Although giant cell tumor of bone (GCT) is generally considered to be an uncommon benign neoplasm, it can pursue an aggressive course with local recurrence and metastasis. Attempts to predict the biological behavior of GCT with histopathological parameters, however, have not been successful. The urokinase-type plasminogen activation system has been implicated in tumor invasion and metastasis and abnormalities of the components of this system have been found in several malignancies. In this study we postulated that the urokinase-type plasminogen activation system associated with bone destruction and local invasion is present in GCT. We therefore evaluated the mRNA levels for urokinase-type plasminogen activator (u-PA), urokinase-type plasminogen activator receptor (u-PAR), and plasminogen activator inhibitor type 1 (PAI-1) by using Northern blot analysis and in situ hybridization in four cases of GCT and spindle-shaped mononuclear cells at the 35th passage from a GCT. Our results showed that giant cell tumors of bone contained variable levels of u-PA, u-PAR, and PAI-1 mRNA, respectively, 2.3, 1.4, and 3.2 kb in size. In situ hybridization showed that u-PA, u-PAR, and PAI-1 mRNA were expressed in both the mononuclear cells and the osteoclast-like giant cells; the signal for u-PA mRNA in the spindle-shaped mononuclear cells was more intense than that in the osteoclast-like multinuclear giant cells. Some spherical mononuclear cells (macrophage-like cells) expressed high levels of PAI-1 mRNA in comparison with the spindle-shaped mononuclear cells. In addition, the 35th passaged spindle-shaped mononuclear cells were used to study the gene expression of u-PA during cell proliferation. The results showed that the level of u-PA mRNA increases after adding 10% fetal calf serum to quiescent cells. The induction was maximal at 16 hours and remained high during 48 hours of treatment. In conclusion, even though osteoclast-like cells are ultimately responsible for the bone resorption of GCT, the mononuclear neoplastic cells of GCT may also be involved in degradation of the extracellular matrix during invasive growth by facilitating the urokinase plasminogen activation system. In addition, our observation of upregulation of u-PA mRNA in spindle-shaped mononuclear cells after serum stimulation indicated that u-PA production may be linked to tumor growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495280      PMCID: PMC1869931     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

Review 1.  The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases.

Authors:  A J Docherty; J O'Connell; T Crabbe; S Angal; G Murphy
Journal:  Trends Biotechnol       Date:  1992-06       Impact factor: 19.536

Review 2.  Plasminogen activator inhibitors: hormonally regulated serpins.

Authors:  P A Andreasen; B Georg; L R Lund; A Riccio; S N Stacey
Journal:  Mol Cell Endocrinol       Date:  1990-01-02       Impact factor: 4.102

Review 3.  Components of the plasminogen-plasmin system in human tumor cell lines.

Authors:  H C Kwaan; H N Keer; J A Radosevich; J F Cajot; R Ernst
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

4.  Expression of Ia and monocyte-macrophage lineage antigens in giant cell tumor of bone and related lesions.

Authors:  L Ling; M J Klein; H A Sissons; G C Steiner; R J Winchester
Journal:  Arch Pathol Lab Med       Date:  1988-01       Impact factor: 5.534

5.  Biologic characterization of human bone tumors. III. Giant cell tumor of bone. A combined electron microscopical, histochemical, and autoradiographical study.

Authors:  A Roessner; D B von Bassewitz; W Schlake; G Thorwesten; E Grundmann
Journal:  Pathol Res Pract       Date:  1984-05       Impact factor: 3.250

Review 6.  Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.

Authors:  P A Andreasen; L Sottrup-Jensen; L Kjøller; A Nykjaer; S K Moestrup; C M Petersen; J Gliemann
Journal:  FEBS Lett       Date:  1994-02-07       Impact factor: 4.124

7.  Giant-cell tumor of bone.

Authors:  M Campanacci; N Baldini; S Boriani; A Sudanese
Journal:  J Bone Joint Surg Am       Date:  1987-01       Impact factor: 5.284

8.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

9.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.

Authors:  V Ellis; N Behrendt; K Danø
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

10.  Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.

Authors:  E G Levin; L Santell
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

View more
  4 in total

Review 1.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

Review 2.  Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Authors:  Mathias Werner
Journal:  Int Orthop       Date:  2006-09-30       Impact factor: 3.075

3.  Determination of β-glucuronidase in human colorectal carcinoma cell lines.

Authors:  S Feng; J D Song
Journal:  World J Gastroenterol       Date:  1997-12-15       Impact factor: 5.742

4.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.